You are here:
  • Home
  • »
  • Products
  • »
  • US Patent for Prefusion RSV F proteins and their use

US Patent for Prefusion RSV F proteins and their use

Steel machining - Customized shape and size →Click on

Ordinary Steel structure OEM&ODM →Click on

Pressure vessel/large tank processing →Click on

Other steel structure processing →Click on

  • Product Description

enta-10k_20190930.htm - SEC

Sep 30,2019 US Patent for Prefusion RSV F proteins and their use#0183;RSV is a single-stranded,negative-sense RNA virus.The RSV genome consists of ten genes that encode for 11 proteins,namely NS1,NS2,N,P,M,SH,G,F,M2-1,M2-2,and L.The F and G proteins are the predominant target proteins for RSV vaccines.Similarly,small molecule therapeutics have focused primarily on the F (or fusion) 5enta-10k_20190930.htm - SECSep 30,2019 US Patent for Prefusion RSV F proteins and their use#0183;RSV is a single-stranded,negative-sense RNA virus.The RSV genome consists of ten genes that encode for 11 proteins,namely NS1,NS2,N,P,M,SH,G,F,M2-1,M2-2,and L.The F and G proteins are the predominant target proteins for RSV vaccines.Similarly,small molecule therapeutics have focused primarily on the F (or fusion) 5Viral protein - definition of Viral protein by The Free Viral protein synonyms,Viral protein pronunciation,Viral protein translation,English dictionary definition of Viral protein. University of Georgia obtains United States patent.Now the CIA has unveiled a grimmer concern that biotechnological advances leading to and engendered by the genome study could yield engineered biological agents

US20160251412A1 - Rsv-specific binding molecule - Google

US20160251412A1 US15/042,656 US201615042656A US2016251412A1 US 20160251412 A1 US20160251412 A1 US 20160251412A1 US 201615042656 A US201615042656 A US 201615042656A US 2016251412 A1 US2016251412 A1 US 2016251412A1 Authority US United States Prior art keywords sequence antibody rsv seq id heavy chain Prior art date 2009-10-06 Legal status (The legalTechnology Development Recent Happenings NIH National United States patent 10,125,172 was issued on November 13,2018 for Conformationally stabilized RSV pre-fusion F proteins.NIAID Inventors (no longer at NIAID) United States patent 10,160,795 was issued on December 25,2018 for Neutralizing antibodies to Ebola virus glycoprotein and their use.NIAID Inventor Dr.Nancy Sullivan United States patent 10,166,285 was issued on January 1,2019 for Structural basis of respiratory syncytial virus subtype ).The SARS-CoV and MERS-CoV are the two major causes of severe pneumonia in human (Song et al.,2019).

Structural basis for immunization with postfusion

Similarly,the structure of the F protein from the respiratory syncytial virus (RSV),which is closely related to the F protein of the paramyxoviruses but has two cleavage sites separating F2 from Structural basis for immunization with postfusion Jun 07,2011 US Patent for Prefusion RSV F proteins and their use#0183;The prefusion and postfusion forms of RSV F each have potential shortcomings as vaccine antigens.Large structural differences between the lollipop-shaped prefusion F trimer and the crutch-shaped postfusion F trimer are apparent even at the resolution of electron microscopy of negatively stained specimens,suggesting that prefusion and postfusion F may be antigenicallySome results are removed in response to a notice of local law requirement.For more information,please see here.Previous123456NextGeoffrey B Hutchinson's research works National Geoffrey B Hutchinson's 9 research works with 38 citations and 801 reads,including Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group

Some results are removed in response to a notice of local law requirement.For more information,please see here.12345NextAn mRNA Vaccine against SARS-CoV-2 Preliminary

Aug 31,2020 US Patent for Prefusion RSV F proteins and their use#0183;The candidate vaccine mRNA-1273 encodes the stabilized prefusion SARS-CoV-2 spike protein. as shown for respiratory syncytial virus F glycoprotein,30 and improved for theirSome results are removed in response to a notice of local law requirement.For more information,please see here.ReViral Announces Grant of Key US Composition of Matter The grant of this important patent in the US and Europe protects certain RSV fusion protein inhibitors discovered by ReViral,including lead pipeline asset RV521,and underscores the novelty of

RI-002,an intravenous immunoglobulin containing high

Oct 16,2017 US Patent for Prefusion RSV F proteins and their use#0183;Enhanced levels of antibody to F protein and G protein (1.5-fold or greater compared to commercial IVIG lots) were observed in RI-002 lots compared to commercial IG,suggesting that selection of donors based on high anti-RSV titers in microneutralization assays enhances anti-RSV antibodies for multiple RSV surface proteins .Plant factories for the production of monoclonal Oct 19,2016 US Patent for Prefusion RSV F proteins and their use#0183;Like animal cells,plant cells bear mechanisms for protein synthesis and posttranslational modification (glycosylation and phosphorylation) that allow them to be seriously considered as factories for therapeutic proteins,including antibodies,with the development of biotechnology.The plant platform for monoclonal antibody production is an attractive approach due to its flexibility,speed Patents by Inventor Peter D.Kwong - US Patent,Patent Aug 23,2016 US Patent for Prefusion RSV F proteins and their use#0183;Abstract The present invention provides immunogens comprising a recombinant Respiratory Syncytial Virus (RSV) F protein stabilized in a prefusion conformation and nucleic acids encoding such immunogens.In particular the present invention provides polypeptides,polynucleotides,compositions,and uses thereof for eliciting an immune response to bovine respiratory syncytial virus

PREFUSION RSV F PROTEINS AND THEIR USE - The United

Oct 19,2017 US Patent for Prefusion RSV F proteins and their use#0183;We claim 1.An isolated immunogen,comprising a recombinant RSV F protein comprising at least one amino acid substitution compared to a native RSV F protein that stabilizes the recombinant RSV F protein in a prefusion conformation; wherein the prefusion conformation comprises an antigenic site US Patent for Prefusion RSV F proteins and their use#216; comprising RSV F residues 62-69 and 196-209 that specifically binds to a D25News and Insights NasdaqGet the latest news and analysis in the stock market today,including national and world stock market news,business news,financial news and moreNeutralizing high affinity human monoclonal antibodies Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof (PAT - US5955364) ' ' BRAMS PETER,' ' CHAMAT Patent United STATES Patent - United States.Application US19960635878 on

Modified RSV F proteins and methods of their use -

Jul 17,2018 US Patent for Prefusion RSV F proteins and their use#0183;The invention claimed is 1.An immunogenic composition comprising a trimeric RSV F protein and a pharmaceutically acceptable carrier,wherein the RSV F protein comprises a deletion of up to 10 amino acids corresponding to the fusion domain of residues 137-146 of SEQ ID NO 2,wherein the RSV F protein induces the production of neutralizing antibodies,wherein the RSV F protein isMichael Lenardo,M.D.NIH National Institute of Allergy Michael Lenardo,M.D.,is the Chief of the Molecular Development of the Immune System Section and the Co-Director,NIAID Clinical Genomics Program.Our laboratory investigates the molecular regulation of T lymphocytes,particularly as it relates to immunological tolerance,apoptosis,and autoimmune diseases such as multiple sclerosis,type 1 diabetes mellitus,and similar diseases.Herbal plants and plant preparations as remedial approach Sep 03,2015 US Patent for Prefusion RSV F proteins and their use#0183;Patent No.US 7008650; Filed November 2,2001 .This invention relates to composition for the treatment of acquired immunodeficiency diseases,especially human immunodeficiency virus (HIV),and its simian and feline counterparts [simian immunodeficiency virus (SIV) and feline immunodeficiency virus (FIV)] and to methods for their use.

Fighting COVID-19 Integrated Micro- and Nanosystems for

Sep 02,2020 US Patent for Prefusion RSV F proteins and their use#0183;The spike protein is critical for binding to host cell receptors to facilitate viral entry into the host cell,while proteins M,E,and N are structural proteins that are necessary for general coronavirus functions.31,32 The NA-based testing of SARS-CoV-2 includes four major steps sample collection,RNA extraction,amplification,and signal Fighting COVID-19 Integrated Micro- and Nanosystems for Sep 02,2020 US Patent for Prefusion RSV F proteins and their use#0183;The spike protein is critical for binding to host cell receptors to facilitate viral entry into the host cell,while proteins M,E,and N are structural proteins that are necessary for general coronavirus functions.31,32 The NA-based testing of SARS-CoV-2 includes four major steps sample collection,RNA extraction,amplification,and signal Essential oils in the treatment of - Wiley Online LibraryMay 26,2015 US Patent for Prefusion RSV F proteins and their use#0183;The main symptoms of pharyngitis and tonsillitis can be characterized by erythematous and swollen tissues.Viruses and bacteria are also responsible for these infections.Peritonsillar abscesses are most common in children (older than 5 years) and in young adults.The most important organisms in this infection are nonsporeforming anaerobes,e.g.Fusobacterium necrophorum.

Class Definition for Class 424 - United States Patent and

(2) Note.The terms mere use or mere application as employed in the definitions of Class 424 and the search notes in other classes which refer to Class 424 are defined to encompass only a single step process and include expressions such as applying,contacting,dipping,spraying,injecting,combusting,administering orally,etc.,recited either along or with recitations such as dosage Cited by 97Publish Year 2013Author Alan Rigter,Ivy Widjaja,Hanneke Versantvoort,Frank E.J.Coenjaerts,Maarten van Roosmalen,Kees Xavier Saelens Inventions,Patents and Patent Applications Sep 10,2019 US Patent for Prefusion RSV F proteins and their use#0183;Abstract The present invention relates to immunoglobulin single variable domains (ISVDs) that are directed against respiratory syncytial virus (RSV).More specifically,it relates to ISVDs that bind to the prefusion form of the fusion (F) protein of RSV.The invention relates further to the use of these ISVDs for prevention and/or treatment of RSV infections,and to pharmaceutical Cited by 44Publish Year 2014Author Peter D.Kwong,Barney S.Graham,Jason S.McLellan,Jeffrey Boyington,Lei Chen,Man Chen,Gwo-Yu CSubstitutions-modified Prefusion RSV F Proteins and their Substitutions-modified Prefusion RSV F Proteins and their Use Collaboration and Licensing Opportunity U.S.Patent Application No.62/314,946 filed 03/29/2016; Publish with us.Guide to

COVID-19 A promising cure for the global panic

Jul 10,2020 US Patent for Prefusion RSV F proteins and their use#0183;Human coronaviruses are predominantly concomitant with upper respiratory tract illnesses ranging from mild to moderate including common cold.Most of the people may be infected with one or more of these viruses at some point in their lifetime (Killerby et al.,2018).The SARS-CoV and MERS-CoV are the two major causes of severe pneumonia in human (Song et al.,2019).Benjamin Pinsky's Profile Stanford ProfilesBenjamin Pinsky is part of Stanford Profiles,official site for faculty,postdocs,students and staff information (Expertise,Bio,Research,Publications,and more).The site facilitates research and collaboration in academic endeavors.An mRNA Vaccine against SARS-CoV-2 PreliminaryAug 31,2020 US Patent for Prefusion RSV F proteins and their use#0183;The candidate vaccine mRNA-1273 encodes the stabilized prefusion SARS-CoV-2 spike protein. as shown for respiratory syncytial virus F glycoprotein,30 and improved for their

Alternative conformations of a major antigenic site on RSV F.

Jul 15,2019 US Patent for Prefusion RSV F proteins and their use#0183;Production of RSV F proteins.Plasmid encoding prefusion-stabilized RSV F (DS-Cav1),subtype A DS-Cav1 with a K209Q substitution,or postfusion RSV F based on subtype A (strain A2) or subtype B (strain B9320) with a C-terminal 6x- or 8x-histidine tag and Strep-tag II was co-transfected with furin into FreeStyle 293-F cells (Invitrogen) at a 4:1 Alternative conformations of a major antigenic site on RSV F.Jul 15,2019 US Patent for Prefusion RSV F proteins and their use#0183;Production of RSV F proteins.Plasmid encoding prefusion-stabilized RSV F (DS-Cav1),subtype A DS-Cav1 with a K209Q substitution,or postfusion RSV F based on subtype A (strain A2) or subtype B (strain B9320) with a C-terminal 6x- or 8x-histidine tag and Strep-tag II was co-transfected with furin into FreeStyle 293-F cells (Invitrogen) at a 4:1 A Protective and Safe Intranasal RSV Vaccine Based on a Aug 12,2013 US Patent for Prefusion RSV F proteins and their use#0183;Different variants of F were analyzed with respect to their conformation and reactivity with neutralizing antibodies,assuming that F protein mimicking the metastable prefusion form of RSV F exposes a more extensive and relevant epitope repertoire than F proteins corresponding to the stable inactive postfusion structure.

Leave a Message

24 Hour steel Machining Response - Contact Now